Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2-Reference-Cited by-同舟云学术

Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2

Published:2024-04 Issue:4 Volume:24 Page:341-343
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Oda Yoshiaki,Kumagai Yuji,Kanai Manabu,Iwama Yasuhiro,Okura Iori,Minamida Takeshi,Yagi Yukihiro,Kurosawa Toru,Chivukula Pad,Zhang Ye,Walson Judd L

Publisher

Elsevier BV

Reference5 articles.

1. Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: a systematic review and meta-analysis;Menegale;JAMA Netw Open,2023

2. Waning of 2-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection accounting for depletion-of-susceptibles bias;Andrejko;Am J Epidemiol,2023

3. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial;Oda;Lancet Infect Dis,2023

4. Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants;Herfst;Lancet Infect Dis,2023

5. Evidence for antibody as a protective correlate for COVID-19 vaccines;Earle;Vaccine,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the design and delivery of RNA vaccines for infectious diseases;Advanced Drug Delivery Reviews;2024-10

2. Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity;Journal of Controlled Release;2024-10

3. Can self-amplifying RNA vaccines and viruses exchange genetic material?;Molecular Therapy;2024-08

4. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials;Nature Communications;2024-05-14

5. Self-amplifying RNA COVID-19 vaccine;Cell;2024-04